Sotorasib

{
  "id": "MLC-T-ONC-007882",
  "term": "Sotorasib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone to treat adults with non-small cell lung cancer that has spread or cannot be removed by surgery, and with panitumumab to treat colorectal cancer that has spread. It is used in patients who have a certain mutation (change) in the KRAS gene and whose cancer was treated with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Sotorasib blocks a protein (KRAS p.G12C) made by the mutated KRAS gene, which may help keep cancer cells from growing and may kill them. It is a type of targeted therapy. Also called Lumakras.",
    "An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation."
  ],
  "synonyms": [
    "Lumakras"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sotorasib/"
}